



## Adam Sperling, MD, PhD

Assistant Professor of Medicine (Hematology)

### CLINICAL OFFICE (PRIMARY)

- **Cancer Center**

875 Blake Wilbur Dr Clinic G

Clinic C

Stanford, CA 94305

Tel (650) 498-6000 Fax (650) 724-5203

### Bio

---

#### BIO

Dr. Sperling received his medical degree and PhD in Biological Chemistry from the University of California, Los Angeles in 2011. He completed his residency in internal medicine at the Brigham and Women's Hospital and his fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. He received board certification from the American Board of Internal Medicine in 2014, in Medical Oncology in 2017 and in Hematology in 2018. He was a member of the staff at the Dana-Farber Cancer Institute and the Brigham and Women's Hospital in Boston from 2018-2026, where he was an Assistant Professor of Medicine at Harvard Medical School. He joined the faculty at Stanford University in 2026, where he is a hematologist and basic and translational researcher in hematologic malignancies. He cares for patients with multiple myeloma and related blood cancers and his research focuses on understanding the mechanisms of disease evolution from pre-malignant conditions and the development of drug resistance in multiple myeloma and other hematologic malignancies.

#### CLINICAL FOCUS

- Hematology

#### ACADEMIC APPOINTMENTS

- Assistant Professor, Medicine

#### PROFESSIONAL EDUCATION

- Board Certification: Hematology, American Board of Internal Medicine (2018)
- Fellowship: Dana Farber Cancer Institute Hematology Oncology Fellowship (2018) MA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2017)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2014)
- Residency: Brigham and Women's Hospital Internal Medicine Residency (2014) MA
- Medical Education: UCLA David Geffen School Of Medicine (2011) CA

## Teaching

---

### STANFORD ADVISEES

#### Postdoctoral Faculty Sponsor

Emily Gallen

## Publications

---

### PUBLICATIONS

- **PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy** *BLOOD*  
Miller, P. G., Sperling, A. S., Mayerhofer, C., McConkey, M. E., Ellegast, J. M., Da Silva, C., Cohen, D. N., Wang, C., Sharda, A., Yan, N., Saha, S., Schluter, C., Schechter, et al  
2023; 142 (24): 2079-2091
- **Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma** *CANCER RESEARCH COMMUNICATIONS*  
Mouhieddine, T. H., Nzerem, C., Redd, R., Dunford, A., Leventhal, M., Sklavenitis-Pistofidis, R., Tahri, S., El-Khoury, H., Steensma, D. P., Ebert, B. L., Soiffer, R. J., Keats, J. J., Mehr, et al  
2023; 3 (12): 2560-2571
- **Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells** *JOURNAL OF CLINICAL INVESTIGATION*  
Sellar, R. S., Sperling, A. S., Slabicki, M., Gasser, J. A., McConkey, M. E., Donovan, K. A., Mageed, N., Adams, D. N., Zou, C., Miller, P. G., Dutta, R. K., Boettcher, S., Lin, et al  
2022; 132 (16)
- **Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenstrom macroglobulinemia** *BLOOD ADVANCES*  
Tahri, S., Mouhieddine, T. H., Redd, R., Lampe, L., Nilsson, K., El-Khoury, H., Su, N., Nassar, A. H., Adib, E., Bindra, G., Abou Alaiwi, S., Trippa, L., Steensma, et al  
2022; 6 (7): 2230-2235
- **Characteristics and Outcomes of Eosinophilic Fasciitis-Associated Monoclonal Gammopathy** *JAMA DERMATOLOGY*  
Mazori, D. R., Kassamali, B., Min, M. S., Schaefer, M., LaChance, A. H., Sperling, A. S., Vleugels, R.  
2021; 157 (12): 1508-1509
- **Facts and Hopes in Multiple Myeloma Immunotherapy** *CLINICAL CANCER RESEARCH*  
Sperling, A. S., Anderson, K. C.  
2021; 27 (16): 4468-4477
- **Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy.** *Blood advances*  
Miller, P. G., Sperling, A. S., Brea, E. J., Leick, M. B., Fell, G. G., Jan, M., Gohil, S. H., Tai, Y., Munshi, N. C., Wu, C. J., Neubergh, D. S., Maus, M. V., Jacobson, et al  
2021; 5 (15): 2982-2986
- **Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide** *NATURE REVIEWS CLINICAL ONCOLOGY*  
Jan, M., Sperling, A. S., Ebert, B. L.  
2021; 18 (7): 401-417
- **Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma** *NATURE COMMUNICATIONS*  
Samur, M., Fulciniti, M., Samur, A., Bazarbachi, A., Tai, Y., Prabhala, R., Alonso, A., Sperling, A. S., Campbell, T., Petrocca, F., Hege, K., Kaiser, S., Loiseau, et al  
2021; 12 (1): 868
- **Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant** *NATURE COMMUNICATIONS*  
Mouhieddine, T. H., Sperling, A. S., Redd, R., Park, J., Leventhal, M., Gibson, C. J., Manier, S., Nassar, A. H., Capelletti, M., Huynh, D., Bustoros, M., Sklavenitis-Pistofidis, R., Tahri, et al

2020; 11 (1): 2996

- **Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of *de novo* MDS** *LEUKEMIA & LYMPHOMA*  
Sperling, A. S., Leventhal, M., Gibson, C. J., Ebert, B. L., Steensma, D. P.  
2020; 61 (3): 728-731
- **Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs** *BLOOD*  
Sperling, A. S., Burgess, M., Keshishian, H., Gasser, J. A., Bhatt, S., Jan, M., Slabicki, M., Sellar, R. S., Fink, E. C., Miller, P. G., Liddicoat, B. J., Sievers, Q. L., Sharma, et al  
2019; 134 (2): 160-170
- **The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia** *NATURE REVIEWS CANCER*  
Sperling, A. S., Gibson, C. J., Ebert, B. L.  
2017; 17 (1): 5-19
- **Differential and limited expression of mutant alleles in multiple myeloma** *BLOOD*  
Rashid, N. U., Sperling, A. S., Bolli, N., Wedge, D. C., Van Loo, P., Tai, Y., Shammas, M. A., Fulciniti, M., Samur, M. K., Richardson, P. G., Magrangeas, F., Minvielle, S., Futreal, et al  
2014; 124 (20): 3110-3117
- **Topoisomerase II binds nucleosome-free DNA and acts redundantly with topoisomerase I to enhance recruitment of RNA Pol II in budding yeast** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Sperling, A. S., Jeong, K., Kitada, T., Grunstein, M.  
2011; 108 (31): 12693-12698
- **Chromatin-dependent binding of the *S* cerevisiae HMGB protein Nhp6A affects nucleosome dynamics and transcription** *GENES & DEVELOPMENT*  
Dowell, N. L., Sperling, A. S., Mason, M. J., Johnson, R. C.  
2010; 24 (18): 2031-2042
- **Histone H3 N-terminus regulates higher order structure of yeast heterochromatin** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Sperling, A. S., Grunstein, M.  
2009; 106 (32): 13153-13159
- **Genetic screens for enhancers of brahma reveal functional interactions between the BRM chromatin-remodeling complex and the Delta-Notch signal transduction pathway in Drosophila** *GENETICS*  
Armstrong, J. A., Sperling, A. S., Deuring, R., Manning, L., Moseley, S. L., Papoulas, O., Piatek, C. I., Doe, C. Q., Tamkun, J. W.  
2005; 170 (4): 1761-1774
- **Ciltacabtagene autoleucl in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial** *NATURE MEDICINE*  
Nadeem, O., dos Santos, D., Nikiforow, S., Bosch-Vilaseca, A., O'Donnell, E., Redd, R., DeBraganca, K. C., Sperling, A. S., Liu, Y., McEntire, C., Arters, F., O'Donnell, C., Kineavy, et al  
2026
- **Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma** *JOURNAL OF CLINICAL ONCOLOGY*  
Aktas Samur, A., Corre, J., Talluri, S., Shah, P., Graffeuil, A., Rivera, J., Fan, Y., Dakiki Korucu, B., Szalat, R., Fulciniti, M., Anderson, K. C., Sperling, A., Parmigiani, et al  
2026; 44 (4): 321-334
- **ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3** *BLOOD CANCER DISCOVERY*  
Fulciniti, M., Yao, Y., Perini, T., Fong Ng, J., Schavgoulidze, A., Deng, S., Cui, J., Encinas Mayoral, J., Ladisa, F., Young, R. M., Epstein, C. B., White, C. M., Ott, et al  
2026; 7 (1): 129-141
- **Putative multiple myeloma susceptibility genes identified by exome sequencing of 347 familial and early-onset cases** *LEUKEMIA*  
Pertesi, M., Demangel, D., Niroula, A., Perrial, E., Escobar, M., Vallee, M., Liacos, C., Samur, M. K., Sperling, A. S., Munshi, N. C., Kastiris, E., Dimopoulos, M. A., McKay, et al  
2026; 40 (1): 235-240

- **Mezigdomide for multiple myeloma: a focus on phase 2 trial data** *EXPERT OPINION ON EMERGING DRUGS*  
Mo, C. C., Liu, Y., Nadeem, O., Midha, S., Laubach, J. P., Salman, T., Nicholson, T., Donnelly, K., Bianchi, G., Sperling, A. S., Hartley-Brown, M. A., Richardson, P. G.  
2025; 30 (3): 209-219
- **Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation.** *Molecular cell*  
Ślabicki, M., Park, J., Nowak, R. P., Roy Burman, S. S., Pellman, J., Zou, C., Razumkov, H., Carreiro, J., Rastogi, S., Goldstein, A., Nagiec, M. M., Donovan, K. A., Che, et al  
2025; 85 (16): 3184-3201.e14
- **International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma** *JOURNAL OF CLINICAL ONCOLOGY*  
Avet-Loiseau, H., Davies, F. E., Samur, M. K., Corre, J., D'Agostino, M., Kaiser, M. F., Raab, M. S., Weinhold, N., Gutierrez, N. C., Paiva, B., Neri, P., Weisel, K., Maura, et al  
2025; 43 (24): 2739-2751
- **Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy** *BLOOD ADVANCES*  
Little, J. S., Pena, A., Kim, E., Yee, A. J., Nadeem, O., Midha, S., Sperling, A. S., Munshi, N. C., Raje, N., Frigault, M. J., Cirstea, D. D., Hammond, S. P.  
2025; 9 (16): 4190-4194
- **Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma** *BLOOD ADVANCES*  
Frenking, J. H., Zhou, X., Rejeski, K., Wagner, V., Costello, P., Hielscher, T., Gatti, L., Kauer, J., Nadeem, O., Mai, E. K., Michel, C. S., Friedrich, M. J., Sedloev, et al  
2025; 9 (16): 4151-4166
- **Two clones, one niche: how CH shapes the MM microenvironment** *BLOOD*  
Sperling, A. S.  
2025; 146 (5): 524-525
- **Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U.S. Myeloma Immunotherapy Consortium.** *Blood cancer discovery*  
Razzo, B. M., Midha, S., Portuguese, A. J., Grajales-Cruz, A. F., De Menezes Silva Corraes, A., Costello, P., Liu, Y., Sperling, A. S., Nadeem, O., Dima, D., Banerjee, R., Cowan, A. J., Afrough, et al  
2025
- **Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis** *BLOOD CANCER JOURNAL*  
Dong, S., Banerjee, R., Khan, A. M., Wang, M., Wang, X., Afghahi, A., Afrough, A., Janakiram, M., Wang, B., Cowan, A. J., Sperling, A. S., Anderson Jr, L. D., Rajkumar, et al  
2025; 15 (1): 48
- **Cytopenias in BCMA CAR T: unraveling inflammatory mechanisms** *BLOOD ADVANCES*  
Sperling, A. S.  
2024; 8 (21): 5527-5528
- **Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.** *Expert review of hematology*  
Liu, Y., Mo, C. C., Hartley-Brown, M. A., Sperling, A. S., Midha, S., Yee, A. J., Bianchi, G., Piper, C., Tattersall, A., Nadeem, O., Laubach, J. P., Richardson, P. G.  
2024; 17 (8): 445-465
- **Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma** *BLOOD CANCER DISCOVERY*  
Ghobrial, I. M., Gormley, N., Kumar, S. K., Mateos, M., Bergsagel, P., Chesi, M., Dhodapkar, M. V., Dispenzieri, A., Fonseca, R., Getz, G., Kastritis, E., Kristinsson, S. Y., Martinez-Climent, et al  
2024; 5 (3): 146-152
- **Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis** *BLOOD CANCER DISCOVERY*

- Saygin, C., Zhang, P., Stauber, J., Aldoss, I., Sperling, A. S., Weeks, L. D., Luskin, M. R., Knepper, T. C., Wanjari, P., Wang, P., Lager, A. M., Fitzpatrick, C., Segal, et al  
2024; 5 (3): 164-179
- **Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies** *JCO PRECISION ONCOLOGY*  
Stevens, M. M., Kimmerling, R. J., Olcum, S., Vacha, M., Labella, R., Minnah, A., Katsis, K., Fujii, J., Shaheen, Z., Sundaresan, S., Criscitiello, J., Niesvizky, R., Rajee, et al  
2024; 8: e2300349
  - **Mezigidomide is effective alone and in combination with Menin inhibition in pre-clinical models of KMT2A-r and NPM1c AML.** *Blood*  
Bourgeois, W., Cutler, J. A., Aubrey, B. J., Wenge, D., Perner, F., Martucci, C., Henrich, J. A., Klega, K., Nowak, R. P., Donovan, K. A., Boileau, M., Wen, Y., Hatton, et al  
2023
  - **A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma** *EXPERT OPINION ON DRUG SAFETY*  
Midha, S., Hartley-Brown, M. A., Mo, C. C., Hossain, S., Nadeem, O., O'Donnell, E. K., Bianchi, G., Sperling, A. S., Laubach, J. P., Richardson, P. G.  
2023; 22 (11): 1049-1071
  - **Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy** *BLOOD ADVANCES*  
Little, J. S., Tandon, M., Hong, J., Nadeem, O., Sperling, A. S., Rajee, N., Munshi, N., Frigault, M., Barmettler, S., Hammond, S. P.  
2023; 7 (18): 5485-5495
  - **Selinexor: Targeting a novel pathway in multiple myeloma** *EJHAEM*  
Mo, C. C., Yee, A. J., Midha, S., Hartley-Brown, M. A., Nadeem, O., O'Donnell, E. K., Bianchi, G., Sperling, A. S., Laubach, J. P., Richardson, P. G.  
2023; 4 (3): 792-810
  - **Clonal Hematopoiesis in Young Women Treated for Breast Cancer** *CLINICAL CANCER RESEARCH*  
Gibson, C. J., Fell, G., Sella, T., Sperling, A. S., Snow, C., Rosenberg, S. M., Kirkner, G., Patel, A., Dillon, D., Bick, A. G., Neuberg, D., Partridge, A. H., Miller, et al  
2023; 29 (13): 2551-2558
  - **High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma** *BLOOD*  
Samur, M., Roncador, M., Samur, A., Fulciniti, M., Bazarbachi, A., Szalat, R., Shammas, M. A., Sperling, A. S., Richardson, P. G., Magrangeas, F., Minvielle, S., Perrot, A., Corre, et al  
2023; 141 (14): 1724-1736
  - **Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19** *BLOOD*  
Miller, P. G., Fell, G. G., Foy, B. H., Scherer, A. K., Gibson, C. J., Sperling, A. S., Burugula, B. B., Nakao, T., Uddin, M. M., Warren, H., Bry, L., Pozdnyakova, O., Frigault, et al  
2022; 140 (18): 1993-1997
  - **Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma** *CANCER*  
O'Donnell, E. K., Shapiro, Y. N., Yee, A. J., Nadeem, O., Hu, B. Y., Laubach, J. P., Branagan, A. R., Anderson, K. C., Mo, C. C., Munshi, N. C., Ghobrial, I. M., Sperling, A. S., Agyemang, et al  
2022; 128 (10): 1996-2004
  - **The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma** *SEMINARS IN ONCOLOGY*  
DeStefano, C. B., Gibson, S. J., Sperling, A. S., Richardson, P. G., Ghobrial, I., Mo, C. C.  
2022; 49 (1): 19-26
  - **Functional dissection of inherited non-coding variation influencing multiple myeloma risk.** *Nature communications*  
Ajore, R., Niroula, A., Pertesi, M., Cafaro, C., Thodberg, M., Went, M., Bao, E. L., Duran-Lozano, L., Lopez de Lapuente Portilla, A., Olafsdottir, T., Ugidos-Damboriena, N., Magnusson, O., Samur, et al  
1800; 13 (1): 151
  - **Development of PDE6D and CK1alpha Degradors through Chemical Derivatization of FPFT-2216.** *Journal of medicinal chemistry*  
Teng, M., Lu, W., Donovan, K. A., Sun, J., Krupnick, N. M., Nowak, R. P., Li, Y., Sperling, A. S., Zhang, T., Ebert, B. L., Fischer, E. S., Gray, N. S.  
1800
  - **Modeling and targeting of erythroleukemia by hematopoietic genome editing.** *Blood*

- Iacobucci, I., Qu, C., Varotto, E., Janke, L. J., Yang, X., Seth, A., Shelat, A., Friske, J. D., Fukano, R., Yu, J., Freeman, B. B., Kennedy, J. A., Sperling, et al  
2021; 137 (12): 1628-1640
- **A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade** *HAEMATOLOGICA*  
Miller, P. G., Sperling, A. S., Gibson, C. J., Pozdnyakova, O., Wong, W. J., Manos, M. P., Buchbinder, E. I., Hodi, F., Ebert, B. L., Davids, M. S.  
2021; 106 (2): 651-654
  - **Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide** *SCIENCE TRANSLATIONAL MEDICINE*  
Jan, M., Scarfo, I., Larson, R. C., Walker, A., Schmidts, A., Guirguis, A. A., Gasser, J. A., Slabicki, M., Bouffard, A. A., Castano, A. P., Kann, M. C., Cabral, M. L., Tepper, et al  
2021; 13 (575)
  - **Association of Clonal Hematopoiesis with Chronic Obstructive Pulmonary Disease.** *Blood*  
Miller, P., Qiao, D., Rojas-Quintero, J., Honigberg, M. C., Sperling, A. S., Gibson, C. J., Bick, A. G., Niroula, A., McConkey, M. E., Sandoval, B., Miller, B., Shi, W., Viswanathan, et al  
2021
  - **Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis** *BLOOD*  
Miller, P. G., Sperling, A. S., Gibson, C. J., Viswanathan, K., Castellano, C., McConkey, M., Ceremsak, J., Taylor, M. S., Birndt, S., Perner, F., Arnason, J., Agrawal, M., Schram, et al  
2020; 136 (26): 3051-3055
  - **Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment** *CANCER*  
Hantel, A., DuMontier, C., Odejide, O. O., Luskin, M. R., Sperling, A. S., Hshieh, T., Chen, R., Soiffer, R., Driver, J. A., Abel, G. A.  
2021; 127 (6): 875-883
  - **Small-molecule-induced polymerization triggers degradation of BCL6** *NATURE*  
Slabicki, M., Yoon, H., Koepfel, J., Nitsch, L., Roy Burman, S. S., Di Genua, C., Donovan, K. A., Sperling, A. S., Hunkeler, M., Tsai, J. M., Sharma, R., Guirguis, A., Zou, et al  
2020; 588 (7836): 164+
  - **Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade** *JCO PRECISION ONCOLOGY*  
Miller, P. G., Gibson, C. J., Mehta, A., Sperling, A. S., Frederick, D. T., Manos, M. P., Miao, B., Hachohen, N., Hodi, F., Boland, G. M., Ebert, B. L.  
2020; 4: 1027-1033
  - **The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K** *NATURE*  
Slabicki, M., Kozicka, Z., Petzold, G., Li, Y., Manojkumar, M., Bunker, R. D., Donovan, K. A., Sievers, Q. L., Koepfel, J., Suchyta, D., Sperling, A. S., Fink, E. C., Gasser, et al  
2020; 585 (7824): 293+
  - **Identification of germline variants in adults with hemophagocytic lymphohistiocytosis** *BLOOD ADVANCES*  
Miller, P. G., Niroula, A., Ceremsak, J. J., Gibson, C. J., Taylor, M. S., Birndt, S., Perner, F., Arnason, J., Sperling, A. S., Agrawal, M., Schram, A. M., Nikiforow, S., Pihan, et al  
2020; 4 (5): 925-929
  - **CHIPing Away at Breast Cancer** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*  
Sperling, A. S., Ebert, B. L.  
2020; 112 (1): 10-11
  - **Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.** *American journal of hematology*  
Garcia, J. S., Bhatt, S., Fell, G., Sperling, A. S., Burgess, M., Keshishian, H., Yilma, B., Brunner, A., Neuberg, D., Carr, S. A., Ebert, B. L., Ballen, K., Stone, et al  
2019
  - **Plasmacytoma presenting as jugular foramen tumor in a young woman with multiple myeloma** *AMERICAN JOURNAL OF HEMATOLOGY*  
How, J., Johnson, P., Corrales, C., Wright, K., Justicz, N., Chen, J. X., Sperling, A. S., Connell, N. T.  
2019; 94 (6): 728-732
  - **Widespread intronic polyadenylation diversifies immune cell transcriptomes** *NATURE COMMUNICATIONS*

- Singh, I., Lee, S., Sperling, A. S., Samur, M. K., Tai, Y., Fulciniti, M., Munshi, N. C., Mayr, C., Leslie, C. S.  
2018; 9: 1716
- **A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia** *AMERICAN JOURNAL OF HEMATOLOGY*  
DeAngelo, D. J., Brunner, A. M., Werner, L., Avigan, D., Fathi, A. T., Sperling, A. S., Washington, A., Stroopinsky, D., Rosenblatt, J., McMasters, M., Luptakova, K., Wadleigh, M., Steensma, et al  
2018; 93 (2): 254-261
  - **Prevalent premalignancy** *BLOOD*  
Sperling, A. S., Ebert, B. L.  
2017; 130 (6): 695-696
  - **Factoring in the missing link** *AMERICAN JOURNAL OF HEMATOLOGY*  
Sethi, N., Manesh, R., Sperling, A., Bresler, S. C., Connell, N. T., Tierney, L. M.  
2017; 92 (1): 110-113
  - **A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma** *BLOOD CANCER JOURNAL*  
Bolli, N., Li, Y., Sathiaseelan, V., Raine, K., Jones, D., Ganly, P., Cocito, F., Bignell, G., Chapman, M. A., Sperling, A. S., Anderson, K. C., Avet-Loiseau, H., Minvielle, et al  
2016; 6: e467
  - **Heterogeneity of genomic evolution and mutational profiles in multiple myeloma** *NATURE COMMUNICATIONS*  
Bolli, N., Avet-Loiseau, H., Wedge, D. C., Van Loo, P., Alexandrov, L. B., Martincorena, I., Dawson, K. J., Iorio, F., Nik-Zainal, S., Bignell, G. R., Hinton, J. W., Li, Y., Tubio, et al  
2014; 5: 2997
  - **γH2A is a component of yeast heterochromatin required for telomere elongation** *CELL CYCLE*  
Kitada, T., Schleker, T., Sperling, A. S., Xie, W., Gasser, S. M., Grunstein, M.  
2011; 10 (2): 293-300
  - **Histone H3 Lysine 56 Acetylation Is Linked to the Core Transcriptional Network in Human Embryonic Stem Cells** *MOLECULAR CELL*  
Xie, W., Song, C., Young, N. L., Sperling, A. S., Xu, F., Sridharan, R., Conway, A. E., Garcia, B. A., Plath, K., Clark, A. T., Grunstein, M.  
2009; 33 (4): 417-427
  - **Genetic Identification of a Network of Factors that Functionally Interact with the Nucleosome Remodeling ATPase *ISWI*** *PLOS GENETICS*  
Burgio, G., La Rocca, G., Sala, A., Arancio, W., Di Gesu, D., Collesano, M., Sperling, A. S., Armstrong, J. A., van Heeringen, S. J., Logie, C., Tamkun, J. W., Corona, D. F. V.  
2008; 4 (6): e1000089
  - **The Drosophila BRM complex facilitates global transcription by RNA polymerase II** *EMBO JOURNAL*  
Armstrong, J. A., Papoulas, O., Daubresse, G., Sperling, A. S., Lis, J. T., Scott, M. P., Tamkun, J. W.  
2002; 21 (19): 5245-5254